SHR-1826
Phase 2Small molecule
Suzhou Suncadia Biopharmaceuticals Co., Ltd.SHR-1826 is one of 175 small molecule programs targeting Patients With Advanced Solid Tumors. It is currently in Phase 2.
6
Indications
6
Total Trials
6
Active Trials
174
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
YL202
MMediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
Carboplatin or Cisplatin
SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
SHR-1826
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2
Remeron
OOrganon and Co
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Treatment
GSKPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatocellular Cancer1 trial
Patients With Advanced Solid Tumors1 trial
Non-Small Cell Lung Cancer1 trial
NSCLC1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR-1826. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details